Centessa Pharma rises on FDA's 'fast-track' tag for bleeding disorder therapy

Centessa Pharmaceuticals

22/05/2023 16:54

** U.S.-listed shares of UK-based drug developer Centessa
Pharmaceuticals PLC  CNTA.O  rise ~4% to $4.77
    ** Company says U.S. FDA has granted "fast-track" status to
its experimental therapy to treat Hemophilia B — a hereditary
bleeding disorder caused by lack of blood clotting factor IX
    ** The therapy, serpinPC, inhibits a potent anticoagulant
protein called activated protein C - CNTA   
    ** FDA's "fast-track" tag is aimed at accelerating
development and review of products which are intended to treat
serious diseases
    ** Including session moves, CNTA's U.S.-listed stock up ~55%
YTD

 (Reporting by Mariam Sunny in Bengaluru)
 ((Mariam.ESunny@thomsonreuters.com;))